• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两种人肾癌细胞系纤溶酶原激活物的特性分析

Characterization of plasminogen activator from two human renal carcinoma cell lines.

作者信息

Nelson N F, Cieplak W, Dacus S C, Prager M D

出版信息

J Cell Physiol. 1986 Mar;126(3):435-43. doi: 10.1002/jcp.1041260315.

DOI:10.1002/jcp.1041260315
PMID:2419348
Abstract

Plasminogen activator (PA) activity was identified in the conditioned medium of two human renal carcinoma cell lines, Cur and Caki-1. PA activity of medium, following chromatography on Con A-Sepharose, was divided into effluent and eluate fractions, the latter obtained after elution with methyl mannoside. The ratio of PA activity in effluent:eluate was 90:10 for Caki-1 and 60:40 for Cur. The PA of both effluent fractions and the Caki-1 eluate fraction was of the urokinase (UK) type. Identification rested on molecular weight determination by zymography (major component with Mr 52,000 and a less prominent component of 93,000), lack of binding to fibrin, inhibition by anti-UK antibodies, and lack of inhibitory effect of anti-tissue type PA (TPA) antibodies or the Erythrina trypsin inhibitor, which inhibits TPA but not UK. PA of the Cur eluate fraction gave a more complex pattern in that it bound significantly to fibrin (like TPA), was completely inhibited by both anti-UK and anti-TPA antibodies, but was unaffected by Erythrina trypsin inhibitor. These results raise the possibility of an unusual PA-like enzyme that immunologically cross reacts with anti-UK and anti-TPA. Most of the PA of both cell lines was secreted in a latent form that could be activated by trypsin treatment. The latency appears to result largely from secretion of urokinase proenzyme, which is consistent with the Mr 52,000 of the major PA species and the insensitivity to diisopropyl fluorophosphate inhibition prior to trypsin activation. However, in addition, a UK binding component was found in the conditioned medium, which produced an Mr 93,000 component by reaction with UK.

摘要

在两种人肾癌细胞系Cur和Caki-1的条件培养基中鉴定出纤溶酶原激活剂(PA)活性。培养基的PA活性经刀豆球蛋白A-琼脂糖凝胶柱层析后,分为流出液和洗脱液部分,后者在用甲基甘露糖苷洗脱后获得。Caki-1流出液与洗脱液中PA活性的比例为90:10,Cur为60:40。两种流出液部分以及Caki-1洗脱液部分的PA均为尿激酶(UK)型。鉴定依据包括通过酶谱法测定分子量(主要成分Mr为52,000,次要成分Mr为93,000)、不与纤维蛋白结合、被抗UK抗体抑制以及抗组织型PA(TPA)抗体或刺桐胰蛋白酶抑制剂无抑制作用(刺桐胰蛋白酶抑制剂抑制TPA但不抑制UK)。Cur洗脱液部分的PA呈现出更复杂的模式,因为它能与纤维蛋白显著结合(类似TPA),被抗UK和抗TPA抗体完全抑制,但不受刺桐胰蛋白酶抑制剂影响。这些结果提示存在一种不寻常的类PA酶,它在免疫反应中与抗UK和抗TPA发生交叉反应。两种细胞系的大部分PA以潜伏形式分泌,可通过胰蛋白酶处理激活。这种潜伏性似乎主要源于尿激酶原酶的分泌,这与主要PA种类的Mr 52,000以及胰蛋白酶激活前对二异丙基氟磷酸抑制不敏感相一致。然而,此外在条件培养基中还发现了一种UK结合成分,它与UK反应产生一个Mr 93,000的成分。

相似文献

1
Characterization of plasminogen activator from two human renal carcinoma cell lines.两种人肾癌细胞系纤溶酶原激活物的特性分析
J Cell Physiol. 1986 Mar;126(3):435-43. doi: 10.1002/jcp.1041260315.
2
Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells.尿激酶型和组织型纤溶酶原激活剂在培养的牛毛细血管内皮细胞中有不同的分布。
J Cell Biochem. 1986;30(1):19-29. doi: 10.1002/jcb.240300104.
3
Characterization of plasminogen activator produced by an established cell line from human ovary.源自人卵巢的一个成熟细胞系所产生的纤溶酶原激活物的特性分析。
J Cell Physiol. 1988 Feb;134(2):253-60. doi: 10.1002/jcp.1041340211.
4
Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.12-O-十四烷酰佛波醇-13-乙酸酯诱导的K562白血病细胞培养物中蛋白水解活性的下调:1型纤溶酶原激活物抑制剂过量导致活性尿激酶耗竭
J Cell Physiol. 1989 Jul;140(1):119-30. doi: 10.1002/jcp.1041400115.
5
Human hepatoma cell line plasminogen activator.人肝癌细胞系纤溶酶原激活剂
J Lab Clin Med. 1983 Oct;102(4):500-8.
6
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.
7
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.
8
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.人胶质瘤细胞系中纤溶酶原激活剂和纤溶酶原激活剂抑制剂的异质性表达谱
Cancer Res. 1990 Aug 15;50(16):4957-61.
9
Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.去势对大鼠前列腺腹叶纤溶酶原激活物活性及1型纤溶酶原激活物抑制剂的影响。
Prostate. 1996 Apr;28(4):239-50. doi: 10.1002/(SICI)1097-0045(199604)28:4<239::AID-PROS5>3.0.CO;2-8.
10
Formation of stable complexes between urokinase and a human urinary component.尿激酶与人尿液成分之间稳定复合物的形成。
Thromb Haemost. 1985 Feb 18;53(1):36-41.

引用本文的文献

1
Extraneuronal noradrenaline transport (uptake2) in a human cell line (Caki-1 cells).人细胞系(Caki-1细胞)中的神经元外去甲肾上腺素转运(摄取2)
Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):404-10. doi: 10.1007/BF00176331.